Considering that VTE ranks as the second major cause of death in cancer patients following cancer progression, there is an urgent need for validated risk scores and effective thromboprophylaxis strategies specifically tailored to CDK4/6i-associated VTE (Khorana et al., 2007; West et al., 2021). The gene discussed is CDK4; the disease is cancer.